Company signals · Biotech & Pharma
Harbour BioMed
1 signal in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: Backdrop: a 104.6 (Hot) Talent Market Index (up 3.6 on the month) with EMEA activity steady (+1.2pts).
Harbour BioMed: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 35 tracked companies.
Signals at Harbour BioMed
Executive hires, departures and board changes at Harbour BioMed
Every leadership-change and senior-hiring signal observed at Harbour BioMed, newest first, each dated and linked to the source record.
Harbour BioMed signals in the last 90 days
1 public signal observed since 9 August 2026, by type.
More signals across Biotech & Pharma
Leadership Change · EMEA
BioMarin Pharmaceutical Inc. →Ian T. Clark elected as new Chair of the Board, replacing retiring Richard A. Meier
Capital Raising · EMEA
mbiomics →mbiomics secured a further €12M, bringing its Series A to €30M to advance microbiome-based therapeutics (as reported in a roundup of European biotech financings).
Geographic Expansion · EMEA
Bio-Techne →Bio-Techne is expanding its GMP manufacturing network with a new facility in Bristol, UK, to scale cell therapy development capabilities alongside existing North American operations.
Product Launch · EMEA
AviadoBio →AviadoBio has presented Phase 1/2 trial data for AVB-101, its investigational gene therapy for frontotemporal dementia with GRN mutations (FTD-GRN), showing dose-dependent increases in cerebrospinal fluid progranulin levels across four ascending doses.
Product Launch · EMEA
Biogen Inc. →Biogen announced 52-week Phase 2 results for litifilimab in cutaneous lupus erythematosus (CLE), demonstrating rapid and durable efficacy. Data supports potential first-in-class therapy positioning. Results presented at EADV 2026 Congress in Vienna. Ongoing Phase 2/3 AMETHYST study progressing.
Product Launch · EMEA
Boehringer Ingelheim →Boehringer Ingelheim announced Phase III trial success for survodutide (BI 456906), a glucagon/GLP-1 receptor dual agonist, achieving 13.1% average weight loss in obesity and type 2 diabetes patients. Results published in NEJM and presented at EASD conference.
Where Harbour BioMed's market lands in our work
- Board Search & Advisory →
Incoming executives reshape governance needs within two quarters.
- Executive Search: EMEA →
Our EMEA practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record
- Data period
- 5 Nov 2026 – 5 Nov 2026 · 1 signals for this company
- Methodology
- How this is computed
- Publisher
- MitchelLake
Last updated